Cipla Shares Plunge 5% as USFDA Flags Partner Pharmathen's Compliance Gaps

• Cipla shares dropped nearly 5% after USFDA disclosed observations on its partner, Pharmathen International.
• Pharmathen is Cipla's contract manufacturing partner for the tumour drug Lanreotide in the US market.
• USFDA observations highlight multiple compliance gaps at Pharmathen's facilities, including contamination prevention and sterile conditions.
• Deficiencies also noted in aseptic processing, laboratory controls, and poor building conditions.
• Nuvama brokerage warns that major manufacturing challenges at Pharmathen could impact Cipla's Lanreotide revenue.

Why It Matters: USFDA's compliance concerns at partner Pharmathen hit Cipla shares, raising revenue worries.